BRAF and thyroid gland carcinoma: To comprehensively investigate the effects of YK-4-279 on aggressive behaviors of thyroid cancer cells, we next used in vitro models to examine the roles of YK-4-279 in oncogenic behaviors of aggressive thyroid cancer cell lines harboring both BRAF V600E and TERT promoter mutations (BCPAP and KHM-5M) or harboring TERT promoter mutation only (Hth7).